Harvard Bioscience (HBIO) Projected to Release Quarterly Earnings on Tuesday

Harvard Bioscience (NASDAQ:HBIO) will likely be releasing its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Harvard Bioscience to post earnings of ($0.21) per share and revenue of $21.45 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:00 AM ET.

Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings data on Tuesday, May 12th. The medical instruments supplier reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.29. The firm had revenue of $20.75 million for the quarter, compared to analyst estimates of $21.20 million. Harvard Bioscience had a negative return on equity of 25.78% and a negative net margin of 11.44%.

Harvard Bioscience Price Performance

Shares of HBIO traded down $0.04 during trading hours on Tuesday, hitting $6.27. 1,361 shares of the company were exchanged, compared to its average volume of 38,973. The company has a market cap of $28.28 million, a price-to-earnings ratio of -2.89 and a beta of 1.49. The firm’s fifty day moving average is $6.11 and its 200 day moving average is $5.80. Harvard Bioscience has a fifty-two week low of $3.75 and a fifty-two week high of $9.40. The company has a quick ratio of 1.06, a current ratio of 1.99 and a debt-to-equity ratio of 3.60.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Harvard Bioscience in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $6.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in HBIO. Bank of America Corp DE raised its position in shares of Harvard Bioscience by 44.4% during the fourth quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after purchasing an additional 11,948 shares during the period. Geode Capital Management LLC lifted its position in shares of Harvard Bioscience by 4.3% during the fourth quarter. Geode Capital Management LLC now owns 460,793 shares of the medical instruments supplier’s stock valued at $308,000 after purchasing an additional 18,923 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Harvard Bioscience by 291.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 49,751 shares of the medical instruments supplier’s stock worth $33,000 after buying an additional 37,057 shares during the last quarter. XTX Topco Ltd purchased a new position in Harvard Bioscience in the fourth quarter worth $26,000. Finally, Jane Street Group LLC grew its position in Harvard Bioscience by 491.9% during the second quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 58,785 shares during the period. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.